CIBC Reaffirms Outperform Rating for Teladoc, Inc. (TDOC)
Teladoc, Inc. (NYSE:TDOC)‘s stock had its “outperform” rating reaffirmed by investment analysts at CIBC in a research note issued to investors on Tuesday. They currently have a $45.00 target price on the health services provider’s stock, up from their prior target price of $40.00. CIBC’s price target would indicate a potential upside of 48.03% from the company’s current price.
A number of other brokerages have also commented on TDOC. Robert W. Baird lowered shares of Teladoc from an “outperform” rating to a “neutral” rating and increased their price target for the stock from $14.00 to $36.00 in a report on Monday, September 18th. KeyCorp reissued a “buy” rating and issued a $37.00 price target on shares of Teladoc in a report on Sunday, September 17th. Zacks Investment Research raised shares of Teladoc from a “sell” rating to a “buy” rating and set a $38.00 price target on the stock in a report on Wednesday, October 4th. BidaskClub lowered shares of Teladoc from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $39.00 target price on shares of Teladoc in a report on Saturday, September 30th. One analyst has rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $39.00.
Shares of Teladoc (TDOC) traded up $2.00 during trading hours on Tuesday, hitting $30.40. 1,820,400 shares of the stock were exchanged, compared to its average volume of 925,269. Teladoc has a 1 year low of $15.65 and a 1 year high of $37.55. The company has a debt-to-equity ratio of 0.83, a quick ratio of 5.08 and a current ratio of 5.08.
In other Teladoc news, CEO Jason N. Gorevic sold 20,000 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $33.47, for a total transaction of $669,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Mark Hirschhorn sold 10,000 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $34.04, for a total transaction of $340,400.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 135,000 shares of company stock worth $4,408,700. 4.47% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in TDOC. Janus Henderson Group PLC purchased a new stake in Teladoc during the 2nd quarter valued at $58,287,000. Bamco Inc. NY boosted its position in Teladoc by 751.9% during the 3rd quarter. Bamco Inc. NY now owns 1,455,900 shares of the health services provider’s stock valued at $48,263,000 after buying an additional 1,285,000 shares during the period. BlackRock Inc. boosted its position in Teladoc by 42.9% during the 2nd quarter. BlackRock Inc. now owns 3,844,402 shares of the health services provider’s stock valued at $133,400,000 after buying an additional 1,154,852 shares during the period. Victory Capital Management Inc. purchased a new stake in Teladoc during the 3rd quarter valued at $35,360,000. Finally, JPMorgan Chase & Co. boosted its position in Teladoc by 65.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,663,600 shares of the health services provider’s stock valued at $92,426,000 after buying an additional 1,057,065 shares during the period.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.